Expression of gp19K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver

Journal of Virology

Volumn 71, Issue 10, 1997, Pages 7623-7628

  Bruder, Joseph T ^a   Jie, Tian ^a   McVey, Duncan L ^a   Kovesdi, Imre ^a  

^a GENVEC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; GLYCOPROTEIN; VIRUS VECTOR;

ADENOVIRUS; ALLELE; ANIMAL TISSUE; ARTICLE; CYTOTOXIC T LYMPHOCYTE; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; GENE TARGETING; GENE THERAPY; HAPLOTYPE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; TRANSGENE; VIRUS EXPRESSION;

EID: 0030880893     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.10.7623-7628.1997     Document Type: Article

References (53)

1. Adesanya, M. R., R. S. Redman, B. J. Baum, and B. C. O'Connell. 1996. Immediate inflammatory responses to adenovirus-mediated gene transfer in rat salivary glands. Hum. Gene Ther. 7:1085-1093.
2. Ahn, K., T. H. Meyer, S. Uebel, P. Sempe, H. Djaballah, Y. Yang, P. A. Peterson, K. Fruh, and R. Tampe. 1996. Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. EMBO J. 15: 3247-3255.
3. Amalfitano, A., C. R. Begy, and J. S. Chamberlain. 1996. Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc. Natl. Acad. Sci. USA 93:3352-3356.
4. Andersson, M., S. Paabo, T. Nilsson, and P. A. Peterson. 1985. Impaired intraceuular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance. Cell 43:215-222.
5. Beier, D. C., J. H. Cox, D. R. Vining, P. Cresswell, and V. H. Engelhard. 1994. Association of human class I MHC alleles with the adenovirus E3/19K protein. J. Immunol. 152:3862-3872.
6. Brough, D. E., A. Lizonova, C. Hsu, V. A. Kulesa, and I. Kovesdi. 1996. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J. Virol. 70:6497-6501.
7. Bruder, J. T. Unpublished data.
8. Burgert, H. G., and S. Kvist. 1985. An adenovirus type 2 giycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell 41:987-997.
9. Burgert, H. G., and S. Kvist. 1987. The E3/19K protein of adenovirus type 2 binds to the domains of histocompatibility antigens required for CTL recognition. EMBO J. 6:2019-2026.
10. Burgert, H. G., J. L. Maryanski, and S. Kvist 1987. E3/19K protein of adenovirus type 2 inhibits lysis of cytolytic T lymphocytes by blocking cell-surface expression of histocompatibility class I antigens. Proc. Natl. Acad. Sci. USA 84:1356-1360.
11. Chinnadurai, G., S. Chinnadurai, and J. Brusca. 1979. Physical mapping of a large-plaque mutation of adenovirus type 2. J. Virol. 32:623-628.
12. Cox, J. H., J. R. Bennink, and J. W. Yewdell. 1991. Retention of adenovirus E19 glycoprotein in the endoplasmic reticulum is essential to its ability to block antigen presentation. J. Exp. Med. 174:1629-1637.
13. Cox, J. H., R. M. L. Buller, J. R. Bennink, J. W. Yewdell, and G. Karupiah. 1994. Expression of adenovirus E3/19K protein does not alter mouse MHC class I-restricted responses to vaccinia virus. Virology 204:558-562.
14. Cox, J. H., J. W. Yewdell, L. C. Eisenlohr, P. R. Johnson, and J. R. Bennink. 1990. Antigen presentation requires transport of MHC class I molecules from the endoplasmic reticulum. Science 247:715-718.
15. DeMatteo, K. P., J. F. Markmann, K. F. Kozarsky, C. F. Barker, and S. E. Raper. 1996. Prolongation of adenoviral transgene expression in mouse liver by lymphocyte subset depiction. Gene Ther. 3:4-12.
16. Engelhardt, J. F., X. Ye, B. Doranz, and J. M. Wilson. 1994. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA 91:6196-6200.
17. Fisher, K. J., H. Choi, J. Burda, S. J. Chen, and J. M. Wilson. 1996. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217:11-22.
18. Gao, G. P., Y. Yang, and J. M. Wilson. 1996. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J. Virol. 70:8934-8943.
19. Ginsberg, H. S., R. L. Horswood, R. M. Chanock, and G. A. Prince. 1990. Role of early genes in pathogenesis of adenovirus pneumonia. Proc. Natl. Acad. Sci. USA 87:6191-6195. (Erratum, 88:681, 1991.)
20. Ginsberg, H. S., U. Lundholm-Beauchamp, R. L. Horswood, B. Pernis, W. S. Wold, R. M. Chanock, and G. A. Prince. 1989. Role of early region 3 (E3) in pathogenesis of adenovirus disease, Proc. Natl. Acad. Sci. USA 86:3823-3827.
21. Ginsberg, H. S., L. L. Moldawer, P. B. Sehgal, M. Redington, P. L. Kilian, R. M. Chanock, and G. A. Prince. 1991. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc. Natl. Acad. Sci. USA 88:1651-1625.
22. Graham, F. L., J. Smiley, W. C. Russell, and R. Nairu. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59-77.
23. Grunhaus, A., S. Cho, and M. S. Horwitz. 1994. Association of vaccinia virus-expressed adenovirus E3-19K glycoprotein with class I MHC and its effects on virulence in a murine pneumonia model. Virology 200:535-546.
24. Guerette, B., J. T. Vilquin, M. Gingras, C. Gravel, K. J. Wood, and J. P. Tremblay. 1996. Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig. Hum. Gene Ther. 7:1455-1463.
25. Haecker, S. E., H. H. Stedman, R. J. Bailce-Gordon, D. B. Smith, J. P. Greelish, M. A. Mitchell, A. Wells, H. L. Sweeney, and J. M. Wilson. 1996. In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum. Gene Ther 7:1907-1914.
26. Jefferies, W. A., and H- G- Burgert. 1990. E3/19K from adenovirus 2 is an immunosubversive protein that binds to a structural motif regulating the intracellular transport of major histocompatibility complex class I proteins. J. Exp. Med. 172:1653-1664.
27. Kaplan, W, J. M., D. Armentano, T. E. Sparer, S. G. Wynn, P. A. Peterson, S. C. Wadsworth, K. K. Couture, S. E. Pennington, J. A. St. George, L. R. Gooding, and A. E. Smith. 1997. Characterization of factors invovled in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum. Gene Ther. 8:45-56.
28. Kay, M. A., A. X. Holterman, L. Meuse, A. Gown, H. D. Ochs, P. S. Linsley, and C. B. Wilson. 1995. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration, Nat, Genet. 11:191-197.
29. Kochanek, S., P. R. Clemens, K. Milani, H. H. Chen, S. Chan, and C. T. Caskey. 1996. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc. Natl. Acad. Sci. USA 93:5731-5736.
30. Rolls, J. K., D. Lei, G. Odom, S. Nelson, W. R. Summer, M. A. Gerber, and J. E. Shellito. 1996. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. Hum. Gene Ther. 7:489-497.
31. Krougliak, V., and F. L. Graham. 1995. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants Hum. Gene Ther. 6:1575-1586.
32. Kumar-Singh, R., and J. S. Chamberlain. 1996. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum. Mol. Genet. 5:913-921.
33. Kvist, S., L. Ostberg, H. Persson, L. Philipson, and P. A. Peterson. 1978. Molecular association between transplantation antigens and cell surface antigen in adenovirus-transformed cell line. Proc. Natl. Acad. Sci. USA 75:5674-5678.
34. Lee, M. G., M. A. Abina, H. Haddada, and M. Perricaudet. 1995. The constitutive expression of the immunomodulatory gp19k protein in E1-, E3-adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Gene Ther. 2:256-262.
35. Lieber, A., C. Y. He, I. Kirillova, and M. A. Kay. 1996. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J. Virol. 70:8944-8960.
36. Paabo, S., B. M. Bhat, W. S. Wold, and P. A. Peterson. 1987. A short sequence in the COOH-terminus makes an adenovirus membrane glycoprotein a resident of the endoplasmic reticulum. Cell 50:311-317.
37. Poller, W., S. Schneider-Rasp, U. Liebert, F. Merklein, P. Thalheimer, A. Haack, R. Schwaab, C. Schmitt, and H. H. Brackmann. 1996. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host. Gene Ther. 3:521-530.
38. Rawle, F. C., A. E. Tollefson, W. S. Wold, and L. R. Gooding. 1989. Mouse anti-adenovirus cytotoxic T lymphocytes. Inhibition of lysis by E3 gp19K but not E3 14.7K. J. Immunol. 143:2031-2037.
39. Routes, J. M., B. A. Metz, and J. L. Cook. 1993. Endogenous expression of E1A in human cells enhances the effect of adenovirus E3 on class I major histocompatibility complex antigen expression. J. Virol. 67:3176-3181.
40. Severinsson, L., I. Martens, and P. A. Peterson. 1986. Differential association between two human MHC class I antigens and an adenoviral glycoprotein. J. Immunol. 137:1003-1009.
41. Sparer, T. E., R. A. Tripp, D. L. Dillehay, T. W. Hermiston, W. S. Wold, and L. R. Gooding. 1996. The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model. J. Virol. 70:2431-2439.
42. Tanaka, Y., and S. S. Tevethia. 1988. Differential effect of adenovirus 2 E3/19K glycoprotein on the expression of H-2Kb and H-2Db class I antigens and H-2Kb- and H-2Db-restricted SV40-specific CTL-mediated lysis. Virology 165:357-366.
43. Tomazin, R., A. B. Hill, P. Jugovic, I. York, P. van Endert, H. L. Ploegh, D. W. Andrews, and D. C. Johnson. 1996. Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. EMBO J. 15:3256-3266.
44. Vilquin, J. T., B. Guerette, I. Kinoshita, B. Roy, M. Goulet, C. Gravel, R. Roy, and J. P. Tremblay. 1995. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum. Gene Ther. 6:1391-1401.
45. Wang, Q., and M. H. Finer. 1996. Second-generation adenovirus vectors. Nat. Med. 2:714-716.
46. Yang, Y., H. C. Ertl, and J. M. Wilson. 1994. MHC class I-restricted cytotoxic T lymphocytes to viral antigens. Immunity 1:433-442.
47. Yang, Y., K. Greenough, and J. M. Wilson. 1996. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther. 3:412-420.
48. Yang, Y., Q. Li, H. C. Ertl, and J. M. Wilson. 1995. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69:2004-2015.
49. Yang, Y., F. A. Nunes, K. Berencsi, E. E. Furth, E. Gonczol, and J. M. Wilson. 1994. Cellular immunity to viral antigens limits E1-deleted. Proc. Natl. Acad. Sci. USA 91:4407-4411.
50. Yang, Y., Q. Su, I. S. Grewal, R. Schilz, R. A. Flavell, and J. M. Wilson. 1996. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J. Virol. 70:6370-6377.
51. Yang, Y., Q. Su, and J. M. Wilson. 1996. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J. Virol. 70:7209-7212.
52. Yang, Y., G. Trinchieri, and J. M. Wilson. 1995. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung [see comments]. Nat. Med. 1:890-893.
53. Yeh, P., J. F. Dedieu, C. Orsini, E. Vigne, P. Denefle, and M. Perricaudet. 1996. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J. Virol. 70:559-565.